Abstract 143P
Background
The prognosis of patients with metastatic renal cell carcinoma (mRCC) has improved markedly with the introduction of molecular-targeted agents and immune checkpoint inhibitors. However, there are few reports on the outcome of systemic therapy for hemodialysis patients with mRCC. The purpose of this study is to evaluate the outcome of the systemic therapy for hemodialysis patients with mRCC.
Methods
We retrospectively studied 253 patients with mRCC (17 hemodialysis patients and 236 non-dialysis patients) treated with systemic therapy at Keio University Hospital in Japan. A progression-free survival (PFS) and overall survival (OS) were evaluated by Kaplan-Meier method.
Results
The pathological diagnosis of the clear cell carcinoma was 52.9% in hemodialysis patients and 82.6% in non-dialysis patients (p=0.007). Hemodialysis patients (10 intermediate risk; 7 poor risk) received first line therapy; 4 received cytokine therapy, 11 received tyrosine kinase inhibitor, 1 received mTOR inhibitor, and 1 received immune checkpoint inhibitor. A median PFS was 6.9 months for hemodialysis patients and 17.0 months for non-dialysis patients (p<0.001), and median OS was 21.2 months for hemodialysis patients and 49.4 months for non-dialysis patients (p<0.001), respectively.
Conclusions
PFS and OS were significantly shorter in hemodialysis patients with mRCC compared to non-dialysis patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
140P - Lenvatinib + everolimus in mRCC that has progressed on immunotherapy: A real-world single center experience
Presenter: CHINNU JOMI
Session: Poster viewing 03
141P - Real-world study of cabozantinib treatment of advanced renal cell carcinoma in Taiwan
Presenter: Yu-Chieh Tsai
Session: Poster viewing 03
144P - Association between immune-related adverse events and survival in metastatic renal cell carcinoma treated with nivolumab plus ipilimumab
Presenter: Takanori Hayase
Session: Poster viewing 03
145P - Treatment outcomes and FGFR alterations in unresectable locally advanced or metastatic urothelial cancer in Taiwan
Presenter: Jian-Ri Li
Session: Poster viewing 03
146P - Comparison of the survival outcomes between primary and secondary muscle-invasive bladder cancer: A propensity score-matched Chinese cohort
Presenter: WAICHAN LOK
Session: Poster viewing 03
Resources:
Abstract
147P - Activity of single-agent PD-1/PD-L1 inhibitors in 1st-line (1L) “platinum-ineligible” patients (pts) with metastatic urothelial cancer (mUC) in real-life clinical practice
Presenter: Javier Molina Cerrillo
Session: Poster viewing 03
149P - A need for clear definitions and improved management for BCG-unresponsive tumors in Asia-Pacific
Presenter: Lui Shiong Lee
Session: Poster viewing 03
Resources:
Abstract
150P - Use of neoadjuvant chemotherapy for non-metastatic muscle-invasive bladder cancer in Asia-Pacific
Presenter: Ravindran Kanesvaran
Session: Poster viewing 03
Resources:
Abstract
Slides